Cargando…
Antimalarial drugs—are they beneficial in rheumatic and viral diseases?—considerations in COVID-19 pandemic
The majority of the medical fraternity is continuously involved in finding new therapeutic schemes, including antimalarial medications (AMDs), which can be useful in combating the 2019-nCoV: coronavirus disease (COVID-19). For many decades, AMDs have been widely used in the treatment of malaria and...
Autor principal: | Grygiel-Górniak, Bogna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254634/ https://www.ncbi.nlm.nih.gov/pubmed/34218393 http://dx.doi.org/10.1007/s10067-021-05805-5 |
Ejemplares similares
-
Antinuclear antibodies in healthy people and non-rheumatic diseases – diagnostic and clinical implications
por: Grygiel-Górniak, Bogna, et al.
Publicado: (2018) -
Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
por: Grygiel-Górniak, Bogna, et al.
Publicado: (2021) -
COVID-19: What Should the General Practitioner Know?
por: Grygiel-Górniak, Bogna, et al.
Publicado: (2021) -
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review
por: Grygiel-Górniak, Bogna
Publicado: (2014) -
Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis
por: Grygiel-Górniak, Bogna, et al.
Publicado: (2023)